A PHP Error was encountered

Severity: 8192

Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated

Filename: helpers/my_audit_helper.php

Line Number: 8900

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Production of uroporphyrinogen III, which is the common precursor of all tetrapyrrole cofactors, from 5-aminolevulinic acid by Escherichia coli expressing thermostable enzymes. | LitMetric

Uroporphyrinogen III (urogen III) was produced from 5-aminolevulinic acid (ALA), which is a common precursor of all metabolic tetrapyrroles, using thermostable ALA dehydratase (ALAD), porphobilinogen deaminase (PBGD), and urogen III synthase (UROS) of Thermus thermophilus HB8. The UROS-coding gene (hemD₂) of T. thermophilus HB8 was identified by examining the gene product for its ability to produce urogen III in a coupled reaction with ALAD and PBGD. The genes encoding ALAD, PBGD, and UROS were separately expressed in Escherichia coli BL21 (DE3). To inactivate indigenous mesophilic enzymes, the E. coli transformants were heated at 70 °C for 10 min. The bioconversion of ALA to urogen III was performed using a mixture of heat-treated E. coli transformants expressing ALAD, PBGD, and UROS at a cell ratio of 1:1:1. When the total cell concentration was 7.5 g/l, the mixture of heat-treated E. coli transformants could convert about 88 % 10 mM ALA to urogen III at 60 °C after 4 h. Since eight ALA molecules are required for the synthesis of one porphyrin molecule, approximately 1.1 mM (990 mg/l) urogen III was produced from 10 mM ALA. The present technology has great potential to supply urogen III for the biocatalytic production of vitamin B₁₂.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00253-013-4904-zDOI Listing

Publication Analysis

Top Keywords

urogen iii
28
alad pbgd
12
coli transformants
12
iii
9
uroporphyrinogen iii
8
common precursor
8
5-aminolevulinic acid
8
escherichia coli
8
iii produced
8
thermophilus hb8
8

Similar Publications

Several life-prolonging therapies with diverse mechanisms of action (MoA) are available for the treatment of metastatic hormone-sensitive/castration-resistant prostate cancer, with many patients requiring multiple lines of therapy. Nevertheless, treatment optimization to further delay disease progression and improve overall survival remains an unmet need. Despite the number of agents with differing MoAs approved for advanced prostate cancer, many patients receive only one or two life-prolonging therapies.

View Article and Find Full Text PDF
Article Synopsis
  • In men with metastatic hormone-sensitive prostate cancer (mHSPC), new treatments help many live longer, but how well each person does can be really different.
  • Researchers are looking at a blood test that counts tiny cancer cells (CTCs) to see if it can help predict a patient’s survival.
  • They studied 503 men to see if the number of CTCs in their blood was linked to how long they lived and how well their treatment worked.
View Article and Find Full Text PDF
Article Synopsis
  • Circulating tumor DNA (ctDNA) can help detect residual cancer after treatment, but its low levels make detection tough; tumor-informed whole-genome sequencing (WGS) offers a solution using numerous mutations for better ctDNA identification.
  • * In a study with 144 stage III colorectal cancer patients and 1283 plasma samples, WGS created a unique mutational fingerprint that improved ctDNA detection and demonstrated excellent reproducibility across labs.
  • * Results showed that ctDNA detection post-surgery and post-chemotherapy strongly predicted cancer recurrence, often identifying it months before standard imaging; the study highlights the potential for WGS to track cancer evolution and treatment effects.*
View Article and Find Full Text PDF

Non-muscle-invasive bladder cancer (NMIBC), which is restricted to the mucosa (stage Ta, carcinoma in situ (CIS)) or submucosa (stage T1), comprises 75% of bladder cancer diagnoses. Intravesical bacillus Calmette-Guérin (BCG) therapy is the standard-of-care initial treatment for high-risk NMIBC; however, a significant proportion of patients have BCG-unresponsive disease. While radical cystectomy is a definitive treatment in this setting, not all patients are willing or able to undergo this complex procedure associated with morbidity, mortality, and decreased quality of life.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!